Publication | Closed Access
Synthesis, Chemical Reactivity as Michael Acceptors, and Biological Potency of Monocyclic Cyanoenones, Novel and Highly Potent Anti-inflammatory and Cytoprotective Agents
61
Citations
39
References
2012
Year
Medicinal ChemistryNovel Monocyclic CyanoenonesHeterocyclicNatural Product SynthesisBiochemistryTranslational PharmacologyMedicineNatural SciencesPharmacological AgentChemical ReactivityOrganic ChemistryBiological PotencyPharmacologyPharmaceutical ChemistryDrug DiscoveryPre-clinical PharmacologyMichael Acceptors
Novel monocyclic cyanoenones examined to date display unique features regarding chemical reactivity as Michael acceptors and biological potency. Remarkably, in some biological assays, the simple structure is more potent than pentacyclic triterpenoids (e.g., CDDO and bardoxolone methyl) and tricycles (e.g., TBE-31). Among monocyclic cyanoenones, 1 is a highly reactive Michael acceptor with thiol nucleophiles. Furthermore, an important feature of 1 is that its Michael addition is reversible. For the inhibition of NO production, 1 shows the highest potency. Notably, its potency is about three times higher than CDDO, whose methyl ester (bardoxolone methyl) is presently in phase III clinical trials. For the induction of NQO1, 1 also demonstrated the highest potency. These results suggest that the reactivity of these Michael acceptors is closely related to their biological potency. Interestingly, in LPS-stimulated macrophages, 1 causes apoptosis and inhibits secretion of TNF-α and IL-1β with potencies that are higher than those of bardoxolone methyl and TBE-31.
| Year | Citations | |
|---|---|---|
Page 1
Page 1